The Life Sciences team advised Aerpio Pharmaceuticals, Inc. on its $45.0 million public offering of common stock and uplisting to the Nasdaq Capital Market. The company’s common stock began trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018. Separately, Goodwin advised Aerpio on its exclusive global license agreement with a wholly-owned subsidiary of Gossamer Bio, Inc., GB004, Inc., for the development and commercialization of Aerpio’s HIF-1 alpha stabilizer, AKB-4924, along with other related compounds.
Aerpio is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company’s lead compound, AKB‐9778, is a small molecule activator of the Tie2 pathway and is in clinical development for diabetic retinopathy.
The Goodwin team advising on the public offering and uplisting included Danielle Lauzon, Stephanie Philbin, James Xu, Marishka DeToy, and Deanna Osganian. Additional details are available in the company’s press release.